Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company will be expanding its MammoView@ Breast Endoscopy product line and will be marketing its MammoView@ Breast Endoscopy Components to hospitals across the Country and Internationally through direct sales channels.
The MammoView@ Instrument line currently contains 6 unique Breast Endoscopy Components which are all featured on the Company's website http://www.solosendoscopy.com/newproductline.html.
"Solos is putting added emphasis on its MammoView@ line of breast endoscopy instrumentation by developing new instruments which will include a new biopsy device to complement its existing line and is in the process of obtaining the necessary regulatory approvals to broaden our markets," stated Bob Segersten, President of Solos Endoscopy, Inc.
Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopy's receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire instrument line which will allow it to market the MammoView@ Breast Endoscopy Components Internationally.
The MammoView@Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise. Solos' intraductal devices are designed to provide direct observation with any endoscopic video system while providing unprecedented image quality, using advanced minimally invasive technologies and tissue preservation techniques.
The MammoView@ instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView@ Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
About Solos Endoscopy, Inc.: Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact: Amanda Segersten email@example.com SOURCE Solos Endoscopy, Inc.
-0- 06/19/2012 /Web Site: http://www.solosendoscopy.com (OTC-PINK:SNDY) / CO: Solos Endoscopy, Inc.
ST: Massachusetts IN: HEA MTC MEQ OTC SU: CXP PDT PRN -- NE27099 -- 0000 06/19/2012 16:12:09 EDT http://www.prnewswire.c